Nascent Biotech, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Sean Carrick
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 623 17th Street Vero Beach FL United States of America 32960
- IPO Date
- Dec 3, 2009
- CIK
- 0001622057
- Website
- nascentbiotech.com
- Similar Companies
- Business
- Nascent Biotech, Inc. (NBIO) is a clinical-stage biopharmaceutical company that develops proprietary human monoclonal antibodies and immunotherapy platforms for the treatment of cancer and other diseases. The company offers Pritumumab, a natural human IgG1 monoclonal antibody targeting ecto-domain vimentin on the surface of adenocarcinomas including brain cancers such as glioblastoma and malignant astrocytoma, as well as lung, breast, colon, pancreas, and melanoma; CLNH5, a monoclonal antibody in development; and MultiPharm, a proprietary platform technology combining multiple agents including antibodies and cytokines for applications in cancer therapy, diabetes, autoimmunity, and transplantation. Nascent Biotech, founded in 2014 and headquartered in North Palm Beach, Florida, operates primarily in the United States with a focus on oncology and immunotherapy targeting vimentin-positive tumors. Recent developments include FDA clearance to initiate Phase II clinical trials for Pritumumab in brain cancer following Phase I completion demonstrating safety and preliminary efficacy; a February 2024 research collaboration with Manhattan BioSolutions to explore antibody-drug conjugates using Pritumumab as the targeting element for vimentin-positive advanced tumors; and engagement of HRA Capital to secure funding for ongoing development. The company maintains orphan drug designation for Pritumumab and holds patents covering its blood-brain barrier penetration capabilities.
Nascent Biotech Presents at the July Emerging Growth Conference
Nascent Prepares for Pivotal Phase II Research with Fresh Manufacturing Run
Nascent Collaborates With Hypospray Pharma on Proprietary Transdermal Delivery System
Nascent Biotech and Manhattan BioSolutions Collaborate to Explore Pritumumab Antibody-Drug Conjugates
Nascent Biotech Receives an Analyst Opinion Suggesting that of the Company is Significantly Under Valued
Nascent Biotech Completes Payment of Variable Convertible Note in Full to Eliminate Dilution Risk
Nascent Biotech Granted Japanese Patent for Crossing Blood-Brain Barrier
Nascent Biotech to Begin Phase II Clinical Trials for Brain Cancer
Nascent Biotech to Present Phase I Clinical Data at American Society of Clinical Oncology Annual Meeting
Nascent Biotech and Manhattan BioSolutions Announce Promising Prelim/Preclinical Results in BCG-Based COVID-19 Vaccine Research Collaboration
Marble Arch Research Publishes Analyst Research Report on Nascent Biotech
Week In Review: LianBio Acquires 2 IBD Candidates In $218 Million Deal
Nascent Biotech and BioRay Pharmaceutical Announce $5,000,000 Exclusive License Agreement for Development and Commercialization of Nascent's Pritumumab
Nascent Biotech Continues Anti-Dilution Campaign with Preemptive Settlement of Outstanding Convertible Note
Nascent Biotech Announces Pre-emptive Elimination of Significant Tranche of Convertible Debt
Nascent Biotech Announces Initial Dosing Underway in Phase 1 Human Trial for Primary and Metastatic Brain Cancer
Nascent Biotech Opens Phase 1 Human Trial to Evaluate Pritumumab as Treatment Option for Primary and Metastatic Brain Cancer
Nascent Biotech Earns US Patent for Crossing Blood-Brain Barrier